TECENTRIQ® (Atezolizumab)

The FDA on May 18, 2016 granted accelerated approval to TECENTRIQ® injection for the treatment of patients with locally advanced or metastatic Urothelial carcinoma, who have disease progression during or following Platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with Platinum-containing chemotherapy. TECENTRIQ® is a Programmed Death-ligand 1 (PD-L1) blocking antibody and is a product of Genentech, Inc.